- Home
- TMQ vs KURA Comparison
TMQ vs KURA Comparison
Compare TMQ & KURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TMQ | KURA |
|---|---|---|
| Founded | 2004 | 2014 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Precious Metals | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 705.7M | 841.6M |
| IPO Year | 2012 | 2015 |
Fundamental Metrics
Financial Performance| Metric | TMQ | KURA |
|---|---|---|
| Price | $3.76 | $9.87 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 11 |
| Target Price | N/A | ★ $25.56 |
| AVG Volume (30 Days) | ★ 2.4M | 2.0M |
| Earning Date | 04-02-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $67,482,000.00 |
| Revenue This Year | N/A | $28.28 |
| Revenue Next Year | N/A | $106.37 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 25.24 |
| 52 Week Low | $1.30 | $5.45 |
| 52 Week High | $11.29 | $12.49 |
Technical Indicators
Market Signals| Indicator | TMQ | KURA |
|---|---|---|
| Relative Strength Index (RSI) | 42.42 | 58.57 |
| Support Level | $3.35 | $8.72 |
| Resistance Level | $4.53 | $10.50 |
| Average True Range (ATR) | 0.28 | 0.52 |
| MACD | -0.04 | 0.07 |
| Stochastic Oscillator | 16.23 | 86.03 |
Price Performance
Historical ComparisonAbout TMQ Trilogy Metals Inc.
Trilogy Metals Inc is an exploration stage company engaged in mineral exploration. The company focuses on exploring and developing its mineral resource properties, which include the Upper Kobuk Mineral Projects (UKMP or UKMP Projects), in the Ambler mining district located in Alaska, the USA. Its properties include the Arctic copper-zinc-gold-silver project and other mineralized targets within a volcanogenic massive sulfide belt, and it also has a bornite carbonate-hosted copper project.
About KURA Kura Oncology Inc.
Kura Oncology Inc is a biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for the treatment of cancer. The company develops small-molecule medicines designed to target cancer signaling pathways in oncology and hematology. Its pipeline includes menin inhibitor ziftomenib for the treatment of acute myeloid leukemia and other hematologic malignancies, as well as additional product candidates such as KO-7246 and darolifarnib being evaluated for solid tumors and other diseases.